Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Looks At Consolidating Stake In Zenotech; Minority Shareholders, Founder Cry Hoarse

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Daiichi Sankyo, the majority equity holder in India's largest drug company Ranbaxy, has encountered a hurdle in its proposal to make an open offer for 20 percent shares in Zenotech Labs. Shareholders of Zenotech Labs have pleaded that the open offer price fixed by Daiichi Sankyo is far less than what Ranbaxy paid to acquire 46 percent of its equity a year ago
Advertisement

Related Content

India's Zenotech Ups Noise Against Daiichi Sankyo; Demands $20 Million In Damages
India's Zenotech Ups Noise Against Daiichi Sankyo; Demands $20 Million In Damages
Daiichi Sankyo Records ¥354 Billion Valuation Loss From Price Drop In Ranbaxy Shares
Advertisement
UsernamePublicRestriction

Register

SC069868

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel